Arkolith/Insider Trading/RGNX/Form 4

Chan Mitchell

Chief Financial OfficerREGENXBIO Inc. (RGNX) · full profile →Form 4 · filed Jan 8, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 6, 2026Grant(A)74K—$0128K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 6, 2026Grant(A)40K—$040K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001789335-26-000002) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML